Zacks Investment Research upgraded shares of INC Research Holdings, Inc. (NASDAQ:INCR) from a hold rating to a buy rating in a research note issued to investors on Wednesday. Zacks Investment Research currently has $58.00 target price on the stock.

According to Zacks, “INC Research Holdings, Inc. is a global contract research organization. It provides the full range of Phase I to Phase IV clinical development services for the biopharmaceutical and medical device industries. Its services include clinical trial management services comprising patient recruitment and retention, project management, clinical monitoring, drug safety/pharmacovigilance, medical affairs, quality assurance, regulatory and medical writing, and functional service; and data services consisting of clinical data management, electronic data capture, and biostatistics. INC Research Holdings, Inc. is headquartered in Raleigh, North Carolina. “

Other analysts also recently issued reports about the company. William Blair downgraded INC Research Holdings from an outperform rating to a market perform rating in a report on Tuesday, June 20th. Jefferies Group LLC reiterated a buy rating and issued a $62.00 price target on shares of INC Research Holdings in a report on Friday, June 16th. TheStreet downgraded INC Research Holdings from a b rating to a c rating in a report on Friday, July 28th. SunTrust Banks, Inc. upgraded INC Research Holdings from a hold rating to a buy rating and increased their price target for the company from $48.00 to $67.00 in a report on Wednesday, May 31st. Finally, KeyCorp raised shares of INC Research Holdings from a sector weight rating to an overweight rating and set a $68.00 price objective for the company in a research report on Monday, June 5th. Five research analysts have rated the stock with a hold rating and six have issued a buy rating to the stock. INC Research Holdings presently has an average rating of Buy and a consensus target price of $62.81.

INC Research Holdings (INCR) traded down 0.57% on Wednesday, reaching $52.30. The company had a trading volume of 630,481 shares. The firm has a market capitalization of $2.83 billion, a price-to-earnings ratio of 32.05 and a beta of 1.41. The stock’s 50-day moving average price is $56.00 and its 200 day moving average price is $52.66. INC Research Holdings has a 52-week low of $40.65 and a 52-week high of $61.10.

INC Research Holdings (NASDAQ:INCR) last announced its quarterly earnings results on Thursday, July 27th. The company reported $0.64 earnings per share (EPS) for the quarter, meeting the consensus estimate of $0.64. INC Research Holdings had a return on equity of 40.69% and a net margin of 5.69%. The firm had revenue of $258.10 million during the quarter, compared to the consensus estimate of $256.76 million. During the same period in the prior year, the firm earned $0.61 EPS. The firm’s quarterly revenue was down .3% compared to the same quarter last year. On average, equities analysts anticipate that INC Research Holdings will post $2.62 earnings per share for the current fiscal year.

TRADEMARK VIOLATION WARNING: This report was originally published by Watch List News and is owned by of Watch List News. If you are reading this report on another site, it was illegally stolen and republished in violation of United States and international copyright laws. The original version of this report can be read at https://www.watchlistnews.com/inc-research-holdings-inc-incr-lifted-to-buy-at-zacks-investment-research/1599021.html.

In other INC Research Holdings news, CFO Gregory S. Rush sold 88,739 shares of the company’s stock in a transaction dated Friday, September 1st. The shares were sold at an average price of $58.99, for a total value of $5,234,713.61. Following the completion of the transaction, the chief financial officer now directly owns 149,301 shares of the company’s stock, valued at approximately $8,807,265.99. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, CFO Gregory S. Rush sold 41,420 shares of the company’s stock in a transaction dated Wednesday, August 30th. The shares were sold at an average price of $58.26, for a total transaction of $2,413,129.20. Following the completion of the transaction, the chief financial officer now directly owns 42,793 shares of the company’s stock, valued at $2,493,120.18. The disclosure for this sale can be found here. Over the last three months, insiders sold 208,876 shares of company stock valued at $12,166,993. 0.24% of the stock is currently owned by corporate insiders.

A number of large investors have recently bought and sold shares of INCR. BlackRock Inc. lifted its position in shares of INC Research Holdings by 82.3% during the second quarter. BlackRock Inc. now owns 6,461,899 shares of the company’s stock worth $378,020,000 after purchasing an additional 2,917,605 shares during the last quarter. Vanguard Group Inc. lifted its position in shares of INC Research Holdings by 2.4% during the second quarter. Vanguard Group Inc. now owns 6,186,393 shares of the company’s stock worth $361,904,000 after purchasing an additional 142,349 shares during the last quarter. State Street Corp lifted its position in shares of INC Research Holdings by 112.8% during the second quarter. State Street Corp now owns 1,769,353 shares of the company’s stock worth $103,508,000 after purchasing an additional 937,864 shares during the last quarter. Janus Henderson Group PLC bought a new position in shares of INC Research Holdings during the second quarter worth about $99,424,000. Finally, Mackenzie Financial Corp lifted its position in shares of INC Research Holdings by 93.1% during the first quarter. Mackenzie Financial Corp now owns 1,196,849 shares of the company’s stock worth $54,876,000 after purchasing an additional 577,034 shares during the last quarter. 54.56% of the stock is owned by institutional investors.

INC Research Holdings Company Profile

INC Research Holdings, Inc is a global contract research organization (CRO). The Company focuses on Phase I to Phase IV clinical development services for the biopharmaceutical and medical device industries. The Company operates through two segments: Clinical Development Services and Phase I Services.

Get a free copy of the Zacks research report on INC Research Holdings (INCR)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for INC Research Holdings (NASDAQ:INCR)

Receive News & Ratings for INC Research Holdings Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for INC Research Holdings Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.